-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
| A variety of key drugs for new coronary pneumonia in my country enter clinical trials |
Beijing, November 17, reporter Yang Shu learned from the Ministry of Science and Technology recently that China has followed the three technical routes of inhibiting virus replication, blocking virus entry into cells, and regulating the human immune system.
A variety of key drugs such as 196 and BRII-198 neutralizing antibody combination therapy, Azvudine, Prokrutamide, etc.
, have all entered the clinical trial stage
.
According to the relevant person in charge of the Ministry of Science and Technology, since the outbreak of the new crown pneumonia epidemic, the State Council’s joint prevention and control mechanism scientific research team, in accordance with the decisions and deployment of the Party Central Committee and the State Council , immediately arranged drug research and development tasks on January 21, 2020.
The scientific research team composed of the Ministry of Science and Technology, the Health Commission, the Ministry of Industry and Information Technology, the National Development and Reform Commission, the Food and Drug Administration, the Bureau of Traditional Chinese Medicine and other departments for drug research and development, organized a national team of superior experts to focus on clinical treatment needs, and fully promote the research and development of effective drugs and treatment technologies Work
.
On the technical route, inhibiting virus replication refers to blocking the replication of the new coronavirus in the human body by inhibiting the key enzymes of virus replication
.
The reporter learned that Azivudine, a key drug developed by Henan Normal University, is a new class 1 anti- AIDS drug
AIDS
Blocking the virus from entering the cell means blocking the virus from entering the cell by preventing the virus S protein from binding to the key receptor that mediates the virus into the human cell
.
Chinese scientists have made many key drug achievements on this technical route
Prokalutamide, developed by Suzhou Kaifeng Pharmaceutical, is a new generation of androgen receptor antagonists under development
.
Three clinical trials conducted in Brazil initially showed that this drug has a good effect on ambulatory and hospitalized patients with mild and moderate new coronary pneumonia, reducing the risk of death of severe patients by 78%, and has obtained emergency use authorization from Paraguay
Made in Keyuan microorganisms and biological Jun real team developed neutralizing antibodies JS016 also blocked viral entry into cells a drug class, has completed Ib and Phase IIa clinical trial of 60 patients in mainland China, the Philippines, Ukraine and other places Join the group work
.
This drug is combined with the drug LY-CoV555 developed abroad to form a combination therapy.
Zhong ASTRI ASTRI
In addition, the Chinese Kexue Yuan developed by Shanghai Institute of Materia Medica FB2001 and VV116 two drugs, at the cellular level also has good antiviral activity, with good pharmacokinetic properties and low toxicity in animal level
.
FB2001 has officially launched Phase I clinical trials in the United States in March 2021
The Academy of Sciences focuses on the new crown pneumonia epidemic
